Research ArticleCancer

Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy

See allHide authors and affiliations

Science Translational Medicine  12 Aug 2020:
Vol. 12, Issue 556, eaaz6606
DOI: 10.1126/scitranslmed.aaz6606

Squaring away tumors

Cancer immunotherapy has been achieving increasing prominence in recent years, but many patients’ tumors still do not respond to existing immunotherapy modalities. One approach that offers promise is activation of the stimulator of interferon gene (STING) pathway, which can promote immune responses within the tumor microenvironment. STING agonists have shown promising results in mice and people, but they require multiple intratumoral injections, which are impractical for many tumors. Lu et al. designed box-shaped microparticles filled with STING agonist and optimized them to release the agonist at appropriate time intervals after being injected into a tumor just once, showing promising results in multiple mouse models of cancer.

View Full Text

Stay Connected to Science Translational Medicine